Ironwood: Growth in LINZESS Sales and Maintains Full Year Guidance

 

• Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) sees an 8% year-over-year increase in LINZESS prescription demand.

• U.S. net sales of LINZESS reach $279 million, marking a 7% increase compared to the previous year.

• Positive final data from STARS Nutrition Phase II study of apraglutide, with topline data for CNP-104 Phase II study expected in Q3 2024.

• Full Year 2023 Guidance reaffirmed by Ironwood Pharmaceuticals Inc (NASDAQ:IRWD).

https://finance.yahoo.com/news/ironwood-pharmaceuticals-inc-irwd-reports-133912960.html